Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin
- Correspondence to: M Odaka Department of Neurology, Dokkyo University School of Medicine, Kitakobayashi 880, Mibu, Shimotsuga, Tochigi 321-0293, Japan;
- Received 29 December 2003
- Accepted 18 November 2004
- Revised 16 November 2004
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous disorder and both clinical course and response to treatment vary widely. Because of the propensity for relapse, CIDP requires maintenance therapy after the initial response to treatment. There is no consensus regarding this in the published literature.
Present report: A patient with CIDP was treated with oral prednisolone and cyclophosphamide pulse therapy but required repeated plasma exchange and intravenous immunoglobulin (IVIg). Treatment with ciclosporin freed the patient from repeated IVIg administration. Therapeutic responses in 14 subsequent cases including three patients who showed improvement with ciclosporin are also presented along with an algorithm of the authors’ suggested protocol for treatment.
Conclusion: Ciclosporin should be considered for patients with intractable CIDP who require repeated IVIg.
- CIDP, chronic inflammatory demyelinating polyneuropathy
- IVIg, intravenous immunoglobulin
- NIS, neuropathy impairment score
- PE, plasma exchange
Competing interests: none declared
Patient consent was obtained.